Quote | Hemostemix Inc. (TSXVC:HEM:CC)
Last: | $0.35 |
---|---|
Change Percent: | 6.06% |
Open: | $0.335 |
Close: | $0.35 |
High: | $0.35 |
Low: | $0.335 |
Volume: | 165,164 |
Last Trade Date Time: | 05/06/2022 04:55:48 pm |
News | Hemostemix Inc. (TSXVC:HEM:CC)
A look at the top 10 most actives in Canada Royal Bank of Canada (RY) fell 0.9% to $135.13 on volume of 3,757,883 shares Rogers Communications Inc. Class B Non-voting Shares (RCI.B) fell 0.5% to $53.81 on volume of 3,042,339 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 7...
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice rel...
Message Board Posts | Hemostemix Inc. (TSXVC:HEM:CC)
Subject | By | Source | When |
---|---|---|---|
Hemostemix got the World Economic Forum's Technology Pioneer Award for their revolutionary autologou | 05/05/2023 9:42:21 AM | ||
Hemostemix ($HEM) is bringing hope to those with ischemic diseases with their new autologous cell th | 05/04/2023 1:49:20 PM | ||
Investors, take note! Biotech leader Hemostemix($HEM) is revolutionizing the treatment of ischemic d | 05/03/2023 3:12:48 PM | ||
Hemostemix ($HEM) is dedicated to developing cell therapy as well as expanding the range of availabl | 05/01/2023 2:21:07 PM | ||
Treatments for sickle cell disease are among the potential products that Hemostemix Inc. (TSXV: $HEM | 04/28/2023 7:14:03 AM |
News, Short Squeeze, Breakout and More Instantly...
Hemostemix Inc. Company Name:
HEM:CC Stock Symbol:
TSXVC Market:
A look at the top 10 most actives in Canada Royal Bank of Canada (RY) fell 0.9% to $135.13 on volume of 3,757,883 shares Rogers Communications Inc. Class B Non-voting Shares (RCI.B) fell 0.5% to $53.81 on volume of 3,042,339 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 7...
Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice rel...
Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results ...